Latest news

March 24, 2025
/
News

FDA-Cleared Digital Treatments are Shaping the Future of Mental Healthcare

New JAMA Study Showcases Clinical Benefits of SleepioRx in Patients with Comorbid Insomnia and Depression Symptoms, Marking 100+ Peer-Reviewed Papers for Big Health
March 10, 2025
/
News
US FDA Grants Clearance for DaylightRx
September 4, 2024
/
News
US FDA Grants Clearance for SleepioRx
August 8, 2024
/
News
Study Finds Spark Direct Effective in Improving Mood Among Adults With Depression
May 23, 2024
/
News

All News

Big Health Raises $75 Million in Series C Funding Led by SoftBank Vision Fund 2
Big Health’s new funding will accelerate the company’s commercial reimbursement model and product platform, including six new digital therapeutics by 2024
January 19, 2022
/
News
Fierce Healthcare names Big Health as one of its 2022 “Fierce 15” Companies
January 10, 2022
/
News
Daily briefings for mental health?
The urgent need for scalable psychological treatment, and other takeaways from the New York Times
December 17, 2021
/
News
The new era of population health: Digital therapeutics for mental health
December 15, 2021
/
News
Scotland becomes first country in the world to make digital therapeutics for anxiety and insomnia available nationally
Through an expanded relationship, NHS Scotland will offer Big Health’s digital therapeutics for anxiety and insomnia to all adults, providing more than five million people access to cognitive behavioural therapy.
October 13, 2021
/
News
Study demonstrates combining digital therapeutics for insomnia and IAPT therapy improves sleep, anxiety, and depression more than therapy alone
Twelve-month evaluation shows the value of incorporating Big Health’s Sleepio, a clinically-based digital therapeutic for insomnia, into a psychological therapies stepped-care model.
September 1, 2021
/
News
Let's talk
For all media-related queries, please get in touch with us.
Who we are
Learn about our mission, leadership, advisors, and investors.